Cover Image
市場調查報告書

Sphingosine-1-磷酸1受體 (S1P受體1/內皮層分化G蛋白耦合受體1/SP1受體EDG-1/CD363/S1PR1/CHEDG1/EDG1) :開發中產品分析

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363128
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
Sphingosine-1-磷酸1受體 (S1P受體1/內皮層分化G蛋白耦合受體1/SP1受體EDG-1/CD363/S1PR1/CHEDG1/EDG1) :開發中產品分析 Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 71 Pages
簡介

本報告提供全球各國的代謝型Sphingosine-1-磷酸1 (以下S1P) 受體的相關產品的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段有的產品的一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • Sphingosine-1-磷酸受體1 (S1P受體1/內皮層分化G蛋白耦合受體1/SP1受體EDG-1/CD363/S1PR1/CHEDG1/EDG1)的概要
  • 治療藥的開發
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • Actelion Ltd
    • Arena Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • Celgene Corporation
    • GlaxoSmithKline Plc
    • Meiji Seika Pharma
    • Novartis AG
  • 藥物簡介
    • AKP-11
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • APD-334
    • BMS-986104
    • CBP-307
    • Cenerimod
    • CP-9531
    • NIBR-0213
    • ozanimod hydrochloride
    • ponesimod
    • siponimod
    • 多發性硬化症的S1P1工作用小分子
    • 多發性硬化症的S1PR1工作用小分子
    • 潰瘍性大腸炎的S1PR1工作用小分子
    • 腫瘤的Sphingosine-1-磷酸較量用小分子
    • 異位性皮膚炎的S1PR1修飾用小分子
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿 (共15件)
  • 附錄

圖表一覽

目錄
Product Code: GMDHC0095TDB

Summary

Global Markets Direct's, 'Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Review, H1 2016', provides in depth analysis on Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted pipeline therapeutics.

The report provides comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)
  • The report reviews Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) Overview
  • Therapeutics Development
    • Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Stage of Development
    • Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Therapy Area
    • Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Indication
  • Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Companies
  • Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • Arena Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • Celgene Corporation
    • GlaxoSmithKline Plc
    • Meiji Seika Pharma Co., Ltd.
    • Novartis AG
  • Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Drug Profiles
    • AKP-11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APD-334 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CBP-307 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cenerimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CP-9531 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NIBR-0213 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ozanimod hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ponesimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • siponimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize S1PR1 for Multiple Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize S1PR1 for Ulcerative Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Dormant Projects
  • Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Discontinued Products
  • Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Featured News & Press Releases
    • May 04, 2016: Study Shows Ozanimod as Effective in Treating Ulcerative Colitis
    • Mar 18, 2016: Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial
    • Feb 18, 2016: Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS
    • Jan 08, 2016: Suzhou Connect Biopharma Reports Positive Phase 1b Result for Novel S1P1 Modulator CBP-307 for Autoimmune Diseases
    • Dec 14, 2015: Akaal Pharma Announces Superior Safety and Comparable Efficacy of Sphingosine 1-Phosphate Receptor-1 (S1P1) Modulator AKP-11 as Compared to Gilenya (Fingolimod) for the Treatment of Multiple Sclerosis
    • Dec 14, 2015: US Patents Issued to Akaal Pharma on S1P1 Receptor Modulators Useful for the Treatment of Autoimmune and Inflammatory Diseases
    • Oct 26, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at UEG Week
    • Oct 19, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at ACG Plenary Session
    • Sep 01, 2015: MS Trial Alert: Investigators Recruiting Worldwide for Phase III Clinical Trial of Oral Ponesimod
    • Jul 30, 2015: Suzhou Connect Biopharma Reports Positive Phase 1a Results for CBP-307, a Novel, Orally-active S1P1 Modulator for Autoimmune Diseases
    • Jul 29, 2015: Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 Receptor Modulator for Autoimmune Diseases
    • Jul 09, 2015: Suzhou Connect Biopharma Announces Patent Issuance Covering CBP-307 - a Clinical-stage Second Generation S1P1 Immune Modulator
    • Jul 01, 2015: Akaal Pharma, Australia extends collaboration with GVK BIO for formulations development services to support Phase 2 Clinical studies for Topical Treatment of Psoriasis
    • Jun 25, 2015: New Data Supporting Gradual Up-Titration Of Ponesimod To Mitigate First-Dose Cardiodynamic Effects To Be Presented At Eacpt 2015
    • Jun 16, 2015: Akaal Pharma Receives Approval to Initiate Phase 2 Clinical Trial for the Topical Treatment of Psoriasis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Actelion Ltd, H1 2016
  • Pipeline by Arena Pharmaceuticals, Inc., H1 2016
  • Pipeline by AstraZeneca Plc, H1 2016
  • Pipeline by Celgene Corporation, H1 2016
  • Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top